Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 6, 2013, Pages 622-629

  Cameron, F L ^a   Gerasimidis, K ^b   Papangelou, A ^b   Missiou, D ^b   Garrick, V ^a   Cardigan, T ^a   Buchanan, E ^a   Barclay, A R ^a   McGrogan, P ^a   Russell, R K ^a  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; STEROID;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG USE; ENTERIC FEEDING; ERYTHROCYTE SEDIMENTATION RATE; EXCLUSIVE ENTERIC FEEDING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SHORT STATURE; THROMBOCYTE COUNT; TREATMENT DURATION; UNDERWEIGHT; WEIGHT GAIN;

ADOLESCENT; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY WEIGHT; CHILD; CROHN DISEASE; ENTERAL NUTRITION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84874113014     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12230     Document Type: Article

References (38)

1. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
2. Hill R, Lewindon P, Muir R, et al,. Quality of life in children with crohn disease. J Pediatr Gastroenterol Nutr 2010; 51: 35-40.
3. Benchimol EI, Fortinsky KJ, Gozdyra P, et al,. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011; 17: 423-39.
4. Henderson P, Hansen R, Cameron FL, et al,. The rising incidence of paediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis 2012; 18: 999-1005.
5. Sawczenko A, Sandhu BK,. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88: 995-1000.
6. Malik S, Mason A, Bakhshi A, et al,. Growth in children receiving contemporary disease specific therapy for Crohn's disease. Arch Dis Child 2012; 97: 698-703.
7. Motil KJ, Grand RJ, Davis-Kraft L, et al,. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1993; 105: 681-91.
8. Lee JJ, Escher JC, Shuman MJ, et al,. Final adult height of children with inflammatory bowel disease is predicted by parental height and patient minimum height Z-score. Inflamm Bowel Dis 2010; 16: 1669-77.
9. Markowitz J, Grancher K, Rosa J, et al,. Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 373-80.
10. Sawczenko A, Ballinger AB, Savage MO, et al,. Clinical features affecting final adult height in patients with pediatric-onset Crohn's disease. Pediatrics 2006; 118: 124-9.
11. Vasseur F, Gower-Rousseau C, Vernier-Massouille G, et al,. Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 2010; 105: 1893-900.
12. Newby EA, Sawczenko A, Thomas AG, et al,. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005; 3: CD003873.
13. Pfefferkorn M, Burke G, Griffiths A, et al,. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009; 48: 168-74.
14. Day AS, Whitten KE, Sidler M, et al,. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008; 27: 293-307.
15. Escher JC, Taminiau JA, Nieuwenhuis EE, et al,. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003; 9: 34-58.
16. Sandhu BK, Fell JM, Beattie RM, et al,. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 (Suppl. 1): S1-S13.
17. Buchanan E, Gaunt WW, Cardigan T, et al,. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther 2009; 30: 501-7.
18. Dziechciarz P, Horvath A, Shamir R, et al,. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 2007; 26: 795-806.
19. Falconer J,. Food reintroduction following exclusive enteral nutrition in paediatric Crohn's disease. Complete Nutrition 2009; 9: 21-3.
20. IBD Working Group of the European Society for Paediatric Gastroenterology HaN. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7.
21. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6.
22. Department of Health. Dietary Reference Values for Food Energy and Nutrient for the United Kingdom. London: Her Majesty's Stationery Office, 1991.
23. Silverberg MS, Satsangi J, Ahmad T, et al,. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl. A): 5-36.
24. Heuschkel RB, Menache CC, Megerian JT, et al,. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31: 8-15.
25. Gavin J, Anderson CE, Bremner AR, et al,. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J Hum Nutr Diet 2005; 18: 337-42.
26. Johnson T, Macdonald S, Hill SM, et al,. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55: 356-61.
27. Day AS, Whitten KE, Lemberg DA, et al,. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol 2006; 21: 1609-14.
28. Fell JM, Paintin M, Arnaud-Battandier F, et al,. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-9.
29. Verma S, Brown S, Kirkwood B, et al,. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95: 735-9.
30. Malik S, Wong SC, Bishop J, et al,. Improvement in growth of children with Crohn's disease following anti-TNF-a therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011; 52: 31-7.
31. Walters TD, Gilman AR, Griffiths AM,. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007; 13: 424-30.
32. Ballinger AB, Azooz O, El Haj T, et al,. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46: 694-700.
33. Bannerjee K, Camacho-Hubner C, Babinska K, et al,. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J Pediatr Gastroenterol Nutr 2004; 38: 270-5.
34. Borrelli O, Cordischi L, Cirulli M, et al,. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4: 744-53.
35. Rubio A, Pigneur B, Garnier-Lenglin H, et al,. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther 2011; 33: 1322-31.
36. Gerasimidis K, Nikolaou CK, Edwards CA, et al,. Serial fecal calprotectin changes in children with Crohn's disease on treatment with exclusive enteral nutrition: associations with disease activity, treatment response, and prediction of a clinical relapse. J Clin Gastroenterol 2011; 45: 234-9.
37. Kugathasan S, Saubermann LJ, Smith L, et al,. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-705.
38. Knight C, El Matary W, Spray C, et al,. Long-term outcome of nutritional therapy in paediatric Crohn's disease. Clin Nutr 2005; 24: 775-9.